The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines
- PMID: 22671714
- DOI: 10.1111/j.1526-4610.2012.02185.x
The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines
Abstract
Background: Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies.
Methods: To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation-II (AGREE-II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence.
Results: Overall, the 3 guidelines were consistent in their recommendations of treatments for first-line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE-II tool.
Conclusion: The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE-II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence.
© 2012 American Headache Society.
Similar articles
-
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society.CMAJ. 1997 May 1;156(9):1273-87. CMAJ. 1997. PMID: 9145054 Free PMC article. Review.
-
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.Neurology. 2019 Sep 10;93(11):500-509. doi: 10.1212/WNL.0000000000008105. Epub 2019 Aug 14. Neurology. 2019. PMID: 31413170 Free PMC article. Review.
-
AAN/AHS update recommendations for migraine prevention in adults.Am Fam Physician. 2013 Apr 15;87(8):584-5. Am Fam Physician. 2013. PMID: 23668450 No abstract available.
-
Preventive Migraine Treatment.Continuum (Minneap Minn). 2015 Aug;21(4 Headache):973-89. doi: 10.1212/CON.0000000000000199. Continuum (Minneap Minn). 2015. PMID: 26252585 Free PMC article. Review.
-
[Treatment guidelines for preventive treatment of migraine].Acta Neurol Taiwan. 2008 Jun;17(2):132-48. Acta Neurol Taiwan. 2008. PMID: 18686655 Review. Chinese.
Cited by
-
Psychotropic Drugs Reemerging as Headache Medicines.CNS Drugs. 2024 Jul 22. doi: 10.1007/s40263-024-01107-x. Online ahead of print. CNS Drugs. 2024. PMID: 39037675
-
Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis.Clin Psychopharmacol Neurosci. 2024 Feb 29;22(1):23-32. doi: 10.9758/cpn.23.1109. Epub 2023 Nov 8. Clin Psychopharmacol Neurosci. 2024. PMID: 38247409 Free PMC article. Review.
-
Use of complementary and alternative medicine in children affected by oncologic, neurologic and liver diseases: a narrative review.Ital J Pediatr. 2023 Nov 15;49(1):152. doi: 10.1186/s13052-023-01554-0. Ital J Pediatr. 2023. PMID: 37968663 Free PMC article. Review.
-
The Potential of Psychedelics for the Treatment of Episodic Migraine.Curr Pain Headache Rep. 2023 Sep;27(9):489-495. doi: 10.1007/s11916-023-01145-y. Epub 2023 Aug 4. Curr Pain Headache Rep. 2023. PMID: 37540398 Review.
-
The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.Pain Ther. 2023 Jun;12(3):655-669. doi: 10.1007/s40122-023-00501-5. Epub 2023 Apr 24. Pain Ther. 2023. PMID: 37093356 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical